Our findings support the proposal that targeting Nrp1 may be a promising therapeutic strategy for malignant glioma through the promotion of anti-tumorigenic polarization of GAMs, in addition to suppressing Nrp1's previously characterized roles in amplifying angiogenic and proliferative signaling in endothelial and glioma-derived cancer cells, respectively. The gene discussed is NRP1; the disease is glioma.